Agents that target cysteine residues of biomolecules and their therapeutic potential

Bibliography

• WOYCECHOWSKY KJ, RAINES RT: Native disulfide bond formation in proteins. CUIT. Opin. Chem. Biol. (2000) 4:533–539.
   PubMed Web of Science ®Google Scholar
• WEDEMEYER WJ, WELKER E, NARAYAN M, SCHERAGA HA: Disulfide bonds and protein folding. Biochemistry (2000) 39:4207–4216.
   PubMed Web of Science ®Google Scholar
• CRAVATT BF, SORENSEN EJ: Chemical strategies for the global analysis of protein function. Curr. Opin. Chem. Biol. (2000) 4:663–668.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DLH: The chemistry of S-nitrosothiols. Acc. Chem Res. (1999) 32:869–876.
   Google Scholar
• VINER RI, WILLIAMS TD, SCHONEICH C: Peroxynitrite modification of protein thiols: oxidation, nitrosyla-tion and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum of Ca-ATP-ase. Biochemistry (1999) 38:12408–12415.
   PubMed Web of Science ®Google Scholar
• VALLEE B, MARET W: Metallothionein III. In: Metallothioneins. Suzuki KT, Imura N, Kimura M (Eds.), Birkhauser, Basel, Switzerland (1993):1–28.
   Google Scholar
• BERTINI I, BRIGANTI F, SCOZZAFAVA A: Zinc proteins. In: Handbook of Metal-Ligand Interactions of Biological Fluids. Bertini I (Ed.), VCH, Weinhaim, Germany (1995) :175–191.
   Google Scholar
• MOCCHEGIANI E, MUZZIOLI M, GIACCONI R: Zinc and immunoresistance to infection in aging: new biological tools. Trends Pharm. Sci. (2000) 21:205–208.
   PubMedGoogle Scholar
• MOCCHEGIANI E, MUZZIOLI M, CIPRIANO C, GIACCONI R: Zinc, T-cell pathways, aging: the role of metallothioneins. Mech. Ageing Dev. (1998) 106:183–204.
   PubMed Web of Science ®Google Scholar
• MOCCHEGIANI E, GIACCONI R, MUZZIOLI M, CIPRIANO C: Zinc, infections and immunosenescence. Mech. Ageing Dev. (2000) 121:21–35.
   PubMedGoogle Scholar
• VALEE BL, AULD DS: Zinc coordination, function and structure of zinc enzymes and other proteins. Biochem-istry (1990) 29:5647–5659.
   PubMed Web of Science ®Google Scholar
• •A classical mini-review on zinc enzymes.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• ••An exhaustive review on the CA inhibitors.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A, MASTROLORENZO A: Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Exp. Opin. Ther. Patents (2001) 11:221–259.
   Web of Science ®Google Scholar
• ••An exhaustive review on bacterial proteases and theirpotential for the development of new generation antibiotics.
   Google Scholar
• SCHAFER SC, DAWES RLF, ELSENHANS B, FORTH W, SCCIMANN K: Metals. In: Toxicology. Marquardt H, Schafer SC, McClellan RD, Welsch F (Eds.), Academic Press (1999):755–804.
   Google Scholar
• BOUHOUCHE N, SYVANEN M, KADO CI: The origin of prokaryotic C2H2 zinc finger regulators. Trends Microbiol. (2000) 8 :77–81.
   PubMedGoogle Scholar
• COX EH, MCLENDON GL: Zinc-dependent protein folding. Curr. Opin. Chem. Bid (2000) 4:162–165.
   PubMedGoogle Scholar
• BUOLAMWINI JK: Novel anticancer drug discovery. Curr. Opin. Chem. Biol. (1999) 3:500–509.
   PubMed Web of Science ®Google Scholar
• OTTO HH, SCHIRMEISTER T: Cysteine proteases and their inhibitors. Chem. Rev. (1997) 97:133–171.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of this family of enzymes and of theirmain types of inhibitors.
   Google Scholar
• VELLA S, PALMISANO L: Antiretroviral therapy: state of the HAART. Antiviral Res. (2000) 45:1–7.
   PubMed Web of Science ®Google Scholar
• JOLY V, YENY P: New trends in antiretroviral therapy of HIV infection. Eur.J. Int. Med. (2000) 11:301–308.
   PubMedGoogle Scholar
• KAUFMANN GR, COOPER DA: Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr. Opin. Microbiol (2000) 3:508–514.
   PubMed Web of Science ®Google Scholar
• RICE WG, SCHAEFFER CA, HARTEN B et al: Inhibition of HIV infectivity by zinc-ejecting C-nitroso compounds. Nature (1993) 361:473–475.
   PubMed Web of Science ®Google Scholar
• RICE WG, SUPKO JG, MALSPEIS L et al.: Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (1995) 270:1194–1197.
   PubMed Web of Science ®Google Scholar
• ••A revolutionary paper on the application of zinc extrusionfrom viral zinc finger proteins, as a novel therapeutic approach for HIV infection.
   Google Scholar
• MELY Y, CORNILLE F, FOURNIE-ZALUSKI MC, DARLIX JL, ROQUES BP, GERARD D: Investigation of zinc-binding affinities of Moloney murine leukemia virus nucleo-capsid protein and related zinc finger and modified peptides. Biopolymers (1991) 31:899–906.
   PubMedGoogle Scholar
• RAMBOARINA S, MORELLER N, FOURNIE-ZALUSKI MC, ROQUES BP: Structural investigation on the require-ment of CCHFIzinc finger type nucleocapsid protein of human immunodeficiency virus 1. Biochemistry (1999) 38:9600–9607.
   PubMedGoogle Scholar
• LOO JA, HOLLER TP, SANCHEZ J, GOGLIOTTI R, MALONEY L, REILY MD: Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2t-dithiobis[benzamides] and benzisothia-zolones. J. Med. Chem. (1996) 39:4313–4320.
   PubMedGoogle Scholar
• DOMAGALA JM, BADER JP, GOGLIOTTI R et al.: A new class of anti-HIV agents targeted towards the nucleo-capsid protein NCp7: the 2,2t-dithiobisbenzamides. Bioorg. Med. Chem. (1997) 5:569–579.
   PubMed Web of Science ®Google Scholar
• HUANG M, MAYNARD A, TURPIN JA et al.: Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc fingers. J. Med. Chem. (1998) 41:1371–1381.
   PubMed Web of Science ®Google Scholar
• ••An excellent paper in which it is shown that zinc extrusionfrom viral zinc finger proteins does not interfere with cellular zinc fingers, validating thus this approach for the treatment of viral diseases.
   Google Scholar
• TURPIN JA, SONG Y, INMAN JK et al.: Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. (1999) 42:67–86.
   PubMed Web of Science ®Google Scholar
• BASRUR V, SONG Y, MAZUR SJ et al.: Inactivation of HIV-1 nucleocapsid protein P7 by pyridinioalkanoyl thiolesters. J. Biol. Chem. (2000) 275:14890–14897.
   PubMedGoogle Scholar
• SCOZZAFAVA A, MENABUONI L, MINCIONE F, BRIGANTIF, MINCIONE G, SUPURAN CT: Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. J. Med. Chem. (2000) 43:4542–4551
   PubMed Web of Science ®Google Scholar
• CASINI A, SCOZZAFAVA A, MINCIONE F, MENABUONI L, ILIES MA, SUPURAN CT: Carbonic anhydrase inhibitors: water soluble 4-sulfamoylphenylthioureas as topical intraocular pressure lowering agents with long lasting effects. J. Med. Chem. (2000) 43:4884–4892.
   PubMed Web of Science ®Google Scholar
• FUJITA M., OTSUKA M, SUGIURA Y: Metal-chelating inhibitors of a zinc finger protein HIV-EP1 remarkable potentiation of inhibitory activity by introduction of SH groups. J. Med. Chem. (1996) 39:503–507.
   PubMedGoogle Scholar
• ZUTSHI R, CHMIELEWSKI J: Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. (2000) 10:1901–1903.
   PubMedGoogle Scholar
• WLODAWER A, GUSTCHINA A: Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta (2000) 1477: 16–34.
   PubMed Web of Science ®Google Scholar
• ••An excellent paper on the HIV protease and its inhibitors,accounted for by one of the most prominent figures in this research field (AW).
   Google Scholar
• FENOUILLET E, BARBOUCHE R, COURAGEOT J, MIQUELIS R: The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. J. Infect. Dis. (2001) 183:744–752.
   PubMed Web of Science ®Google Scholar
• ••This papers demonstrates the involvement of PDI in HIVentry within the cell and forms the basis for design of novel anti-HIV therapies based on PDI inhibitors.
   Google Scholar
• FRATERNALE A, CASABIANCA A, TONELLI A, CHIARAN- TINT L, BRANDI G, MAGNANI M: New drug combination for the treatment of murine AIDS and macrophage protection. Eur.j Clin. Invest. (2001) 31:248–252.
   PubMed Web of Science ®Google Scholar
• ••A novel combination therapy highly effective in thetreatment of murine AIDS, which includes agents able to eradicate the virus from places difficult to access by the enzyme inhibitors used in conventional HAART.
   Google Scholar
• AUBORN KJ, CARTER TH: Treatment of papillomavirus gynecologic infections. Clin. Lab. Med. (2000) 20:407–422.
   PubMed Web of Science ®Google Scholar
• MCGLENNEN RC: Human papillomavirus oncogenesis. Clin. Lab. Med. (2000) 20:383–406.
   PubMed Web of Science ®Google Scholar
• HARWOOD CA, SURENTHERAN T, MCGREGOR JM et al.: Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocom-petent individuals. J Med. Virol. (2000) 61:289–297.
   PubMed Web of Science ®Google Scholar
• ISHIJI T, KAWASE M, HONDA M, NIIMURA M, YOSHIMURA E, MATSUKURA T: Distinctive distribution of human papillomavirus Type 16 and Type 20 in the tonsillar and the skin carcinomas of a patient with epidermodysplasia verruciformis. Br. J. Dermatol (2000) 143:1005–1010.
   PubMed Web of Science ®Google Scholar
• DAHL MV: Irniquimod: an immune response modifier. J. Am. Acad. Dermatol (2000) 43:51–55.
   Google Scholar
• TONG X, HOWLEY PM: The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc. Natl. Acad. Sci. USA (1997) 94:4412–4417.
   PubMedGoogle Scholar
• KAO WH, BEAUDENON SL, TALIS AL, HUIBREGTSE JM, HOWLEY PM: Human papillomavirus Type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-pr otein ligase. j Vim/. (2000) 74:6408–6417.
   Google Scholar
• SASAGAWA T, MINEMOTO Y, BASHA W et al.: A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses. Virus Res. (2000) 67:127–139.
   PubMedGoogle Scholar
• GROSSMAN SR, LAIMINS LA: E6 protein of humanpapillomavirus Type 18 binds zinc. Oncogene (1989) 4:1089–1093.
   PubMedGoogle Scholar
• BEERHEIDE W, BERNARD HU, TAN YJ, GANESAN A, RICEWG, TING AE: Potential drugs against cervical cancer: zinc-ejecting inhibitors of human papillomavirus Type 16 E6 oncoprotein. J Natl. Cancer Inst. (1999) 91:1211–1220.
   PubMed Web of Science ®Google Scholar
• BEERHEIDE W, SIM MM, TAN YJ, BERNARD HU, TING AE: Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg. Med. Chem. (2000) 8:2549–2560.
   PubMed Web of Science ®Google Scholar
• ••An excellent paper on compounds producing zinc ejectionfrom HPV zinc fingers, with the possibility to apply such derivatives as a new treatment of papilloma viruses.
   Google Scholar
• BAUM EZ, DING WD, SIEGEL MM et al: Flavins inhibit human cytomegalovirus ULSO protease via disulfide bond formation. Biochemistry (1996) 35:5847–5855.
   PubMedGoogle Scholar
• BAUM EZ, SIEGEL MM, BEBERNITZ GA et al: Inhibition of human cytomegalovirus ULSO protease by specific intramolecular disulfide bond formation. Biochemistry (1996) 35:5838–5846.
   PubMedGoogle Scholar
• ERTL P, COOPER D, ALLEN G, SLATER MJ: 2-Chloro-3-substituted-1,4-naphthoquinone inactivators of human cytomegalovirus ULSO protease. Bioorg. Med. Chem. Lett. (1999) 9:2863–2866.
   PubMedGoogle Scholar
• MEDINA JC, SHAN B, BECKMANN H et al: Novel antineo-plastic agents with efficacy against multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. (1998) 8:2653–2656.
   PubMed Web of Science ®Google Scholar
• ••An excellent paper on the design of a new class of antitu-mour drugs, with a completely new mechanism of action.
   Google Scholar
• MEDINA JC, ROCHE D, SHAN B et al.: Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. Bioorg. Med. Chem. Lett. (1999) 9:1843–1846.
   PubMed Web of Science ®Google Scholar
• SHAN B, MEDINA JC, SANTHA E et al.: Selective, covalent modification of I3-tubulin residue Cys-239 by 1138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Nati Acad. Sci. USA (1999) 96:5686–5691
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Arylsulfonyl-N,N-diethyl-dithiocarbamates: a novel class of antitumor agents. Bioorg. Med. Chem. Lett. (2000) 10:1887–1891.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Arylsulfonyl-N,N-dialkyl-dithiocarbamates as tumor cell growth inhibitors: novel agents targeting 13-tubulin?./. Enz. Inhib. (2001) 16:In press.
   Google Scholar
• SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonyl sulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and W. Bioorg. Med. Chem. Lett. (2000) 10:1117–1120.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, BRIGANTI F, TILLI S, CHEGWIDDEN WR,SCOZZAFAVA A: Carbonic anhydrase inhibitors. Sulfonamides as antitumor agents? Bioorg. Med. Chem. (2001) 9:703–714.
   PubMed Web of Science ®Google Scholar
• WITTINGHOFER A, WALDMANN H: Ras - A molecular switch involved in tumor formation. Angew. Chem. Int. Ed (2000) 39:4192–4214.
   PubMedGoogle Scholar
• ••An excellent, comprehensive review on the Ras protein.
   Google Scholar
• COHEN LH, PIETERMAN E, VAN LEEUWEN REW et al:Inhibitors of prenylation of Ras and other G-proteins and their applications as therapeutics. Biochem. Pharmacol (2000) 60:1061–1068.
   PubMedGoogle Scholar
• HILL BT, PERRIN D, KRUCZYNSKI A: Inhibition ofRas-targeted prenylation: protein farnesyl transferase inhibitors revisited. Grit. Rev. Oncol. Hematol (2000) 33:7–23.
   PubMed Web of Science ®Google Scholar
• HIGHTOWER K, CASEY PJ, FIERKE CA: Farnesylation of nonpeptidic thiol compounds by protein farnesyl-transferase. Biochemistry (2001) 40:1002–1010.
   PubMedGoogle Scholar
• MORGAN B, ZAKS A, DODDS DR, LIU J, JAIN R, MEGATI S et al.: Enzymatic kinetic resolution of atropisomers: synthesis of a key intermediate of the farnesyl protein transferase inhibitor 5CH66336. j Org. Chem. (2000) 65:5451–5460.
   PubMed Web of Science ®Google Scholar
• FATOUROS D, GORTZI 0, KLEPETSANIS P, ANTIMISIRIASSG, STUART MCA, BRISSON A, IOANNOU PV: Prepara-tion and properties of arsonolipids containing liposomes. Chem. Phys. Lipids (2001) 109:75–89.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, SERVES SV, IOANNOU PV: Carbonic anhydrase inhibitors. Part 33 Isozyme II inhibition with 2,3-dihydroxypropylarsonic acids and arsonolipids.j Inorg. Biochem. (1996) 62:207–212.
   Google Scholar
• TIMOTHEATOU D, IOANNOU PV, SCOZZAFAVA A, BRIGANTI F, SUPURAN CT: Carbonic anhydrase inhibi-tors. Part 42 Carbonic anhydrase interaction with © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(5) lipothioarsenites: a novel class of isozymes I and II inhibitors. Metal Based Drugs (1996) 3:263–268.
   Google Scholar
• IOANNOU PV, KORDALIS NL, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Part 87 Inhibition of carbonic anhydrase isozymes I, II and IV with arsinolipids. Main Group Met. Chem. (1999) 22:693–695.
   Google Scholar
• DRINGEN R: Metabolism and functions of glutathione in brain. Progr. Neurobioi (2000) 62:649–671.
   PubMed Web of Science ®Google Scholar
• VAN BLADEREN PJ: Glutathione conjugation as a bioactivation reaction. Chem. Biol. Interact. (2000) 129:61–76.
   PubMed Web of Science ®Google Scholar
• LANDI S: Mammalian class theta GST and differentialsusceptibility to carcinogenesis: a review. Mutation Res. (2000) 463:247–283.
   PubMed Web of Science ®Google Scholar
• CONROY CW, SCHWAM H, MAREN TH: The non-enzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metab. Dispos. (1984) 12:614–618.
   PubMed Web of Science ®Google Scholar
• KISHIDA K, SAIDA N, YAMAMURA N, IWAI Y, SASABE T: cysteine conjugate of methazolamide is metabolized by 13-lyase. j Pharm. Sci. (2001) 90:224–233.
   PubMedGoogle Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors. Curr. Med. Chem. (2001):In press.
   Google Scholar
• WOLTERSDORF W, SCHWAM H, BICKING JB et al.: Topically active carbonic anhydrase inhibitors. 1 O-Acyl derivatives of hydroxybenzothiazole-2-sulfonamide. J Med. Chem. (1989) 32:2486–2492.
   Google Scholar
• IM WB, SIH JC, BLAKEMAN DP, MCGRATH JP: Omepra-zole, a specific inhibitor of gastric 11±/K+-ATP-ase, is an Htactivated oxidizing agent of sulfhydryls groups. J Biol. Chem. (1985) 260:4591–4597.
   PubMed Web of Science ®Google Scholar
• SACHS G, SHIN JM, BRIVING C, WALLMARK B, HERSEY S: The pharmacology of the gastric acid pump: the H+/K+-ATP-ase. Ann. Rev. Pharmacol. Toxicol. (1995) 35:277–305.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, BRIGANTI F, SCOZZAFAVA A: Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enz. Inhib. (1997) 12:175–190.
   Google Scholar
• SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Novel compounds containing S-NH moieties in their molecule: sulfenamido-sulfonamides, sulfenimido-sulfon amides and their interaction with isozymes I, II and IV. J Enz. Inhib. (1998) 13:419–442.
   Google Scholar
• MALLIS RJ, POLAND BW, CHATTERJEE TK et al.: Crystal structure of S-glutathiolated carbonic anhydrase III. FEBS Lett. (2000) 482:237–241.
   PubMed Web of Science ®Google Scholar
• ANDERSON PM, KORTE JJ, HOLCOMB TA, CHO YG, SON CM, SUNG YC: Formation of intersubunit disulfide bonds and properties of the single histidine and cysteine residues in each subunit relative to the decameric structure of cyanase. J Biol. Chem. (1994) 269:15036–15045.
   PubMedGoogle Scholar
• SHARMA HK: The fast-reacting sulfhydryl group of ratmuscle phosphoglycerate kinase is necessary for activity and maintenance of tertiary structure. Biochemistry (1982) 21:6661–6668.
   PubMed Web of Science ®Google Scholar
• CZERSKI L, SANDERS CR: Thiol modifications ofdiacylglycerol kinase: dependence upon site membrane disposition and reagent hydrophobicity. FEBS Lett. (2000) 472:225–229.
   PubMedGoogle Scholar
• REDDY S, JONES AD, CROSS CE, WONG PS, VAN DERVLIET A: Inactivation of creatine kinase by 5-glutathiolation of the active site cysteine residue. Biochem. J. (2000) 347:821–827.
   PubMedGoogle Scholar
• FENG YH, SAAD Y, KARNIK SS: Reversible inactivation of AT2 angiotensin II receptor from cysteine-disulfide bond exchange. FEBS Lett. (2000) 484:133–138.
   PubMedGoogle Scholar
• HASHIMOTO M, MAJIMA E, HATANAKA T et al.: Irreversible extrusion of the first loop facing the matrix of the bovine heart mitochondrial ADP/ATP carrier by labeling Cys56 residue with the SH reagent methyl methanethiosulfonate. J. Biochem. (Tokyo) (2000) 127:443–449.
   PubMedGoogle Scholar
• LOO TW, CLARKE DM: Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Nati Cancer Inst. (2000) 92:898–902.
   PubMed Web of Science ®Google Scholar
• LOO TVV, CLARKE DM: Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol modifications techniques. Biochim. Biophys. Acta (1999) 1461:315–325.
   PubMedGoogle Scholar
• MALLIS RJ, THOMAS JA: Effect of 5-nitrosothiols on cellular glutathione and reactive protein sulfhydryls. Arch. Biochem. Biophys. (2000) 383:60–69.
   PubMedGoogle Scholar
• SHEN XM, DRYHURST G: Influence of glutathione on the oxidation chemistry of 5-S-cysteinyldopamine: potentially neuroprotective reactions of relevance to Parkinson's disease. Tetrahedron (2001) 57:393–405.
   Google Scholar
• NAISBITT DJ, VILAR FJ, STALFORD AC, WILKINS EGL,PIRMOHAMED M, PARK BK: Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole in HIV infection. AIDS Res. Hum. Retrov. (2000) 16:1929–1938.
   PubMed Web of Science ®Google Scholar
• CAVALLINI L, ALEXANDRE A: Oral N-acetylcysteineincreases the production of anti-HIV chemokines in peripheral blood mononuclear cells. Life Sci. (2000) 67:147–154.
   PubMedGoogle Scholar
• SENGLE G, JENNE A, ARORA PS et al.: Synthesis,incorpo-ration efficiency and stability of disulfide bridged functional groups at RNA 5'-ends. Bioorg. Med. Chem. (2000) 8:1317–1329.
   PubMedGoogle Scholar